Back to Feed
ClinicalTrials.gov|Clinical Trial
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)
University of Florida
Abstract
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ pediatric high-grade glioma Phase: PHASE1 Status: ACTIVE_NOT_RECRUITING Conditions: High-grade Glioma Interventions: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Keywords
High-grade Glioma